Pathology contributes roughly 85% of group revenue, while the company is also the second-largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia, earning about 40% of group revenue in Australia and New Zealand, 25% in the US, and 35% in Europe. Recent acquisitions like PathologyWatch and Synlab have demonstrated a proactive approach to growth.
Cyborg Score Rationale
Sonic Healthcare's revenue grew 7.56% to $9.65 billion in fiscal year 2025, demonstrating solid organic and acquisition-driven growth. However, shareholders are pushing for a break-up of the company as new boss Jim Newcombe reviews the business, signaling governance concerns that temper the outlook.
Top Insights
Largest medical laboratory provider in Australasia and Europe and third largest in the US
Expanding into advanced diagnostics through partnerships like Microba Life Sciences for infectious disease testing and Harrison.ai for clinical AI solutions in pathology
Dr Jim Newcombe became CEO and Managing Director from 20th November 2025, signaling a transition in leadership strategy
Exposed to regulatory risks from bulk-billing changes in Australia impacting diagnostic provider margins
Named Competitors
Quest Diagnostics — Clinical laboratory and diagnostic imaging services in US
LabCorp — Diagnostic laboratory services and drug testing
Australian Clinical Labs — Pathology and diagnostic imaging in Australia
Healius — Australian pathology and medical services provider
Recent Developments
(November 2025) Leadership transition with Dr Jim Newcombe becoming new CEO
(2025) Acquisition of Swiss laboratory network Synlab Suisse
(2025) Partnership with Harrison.ai to develop clinical AI solutions in pathology
(2022) Acquired 19.99% stake in Microba Life Sciences for advanced testing capabilities
Open the full interactive Sonic Healthcare Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.